Novel RNAVaccine Report: A Case Report of COVID-19 MRNA Vaccine Induced Immune Thrombocytopenic Purpura

Abstract

We describe a 74-year-old female who presented with thrombocytopenia 20 days after receiving her first dose of the novel mRNA vaccine. After an exhaustive workup, Immune Thrombocytopenia was diagnosed secondary to her recent mRNA vaccine administration. She was treated aggressively with high-dose steroids and IVIG, with adequate response.